Without Rebates, Evidence Could Be Key For Formulary Placement

By Rachel Cohrs
April 18, 2019 at 5:55 PM
Information about a drug’s effectiveness compared to alternative treatments could help drug makers argue for formulary placement in a system without rebates, Deloitte’s head of life sciences said. Some patient advocates worry that using comparative effectiveness data in coverage decisions could limit access, as different drugs work better for different patients. Greg Reh, Deloitte’s vice chairman and leader of its life science division, said the Trump administration’s point-of-sale rebate proposal could force drug companies to compete more directly on value...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.